Oxana Beskrovnaya - Mar 14, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Scientific Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Mar 14, 2023
Transactions value $: -$18,875
Form type: 4
Date filed: 3/15/2023, 05:48 PM
Previous filing: Dec 13, 2022
Next filing: Jun 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Sale	-$18.9K	-1.42K	-1.57%	$13.33	88.7K	Mar 14, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2	Includes 72,258 unvested RSUs.

Content

Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Includes 72,258 unvested RSUs.